2023
Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCholangitisCholangitis, SclerosingFemaleHumansImmunologic FactorsInflammatory Bowel DiseasesMaleMiddle AgedRetrospective StudiesRisk FactorsConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedArthritisFemaleHumansInflammatory Bowel DiseasesMaleMiddle AgedRetrospective StudiesConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2018
Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease
Conley S, Jeon S, Proctor DD, Sandler RS, Redeker NS. Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease. Journal Of Nursing Scholarship 2018, 50: 473-481. PMID: 29971936, PMCID: PMC6120775, DOI: 10.1111/jnu.12409.Peer-Reviewed Original ResearchConceptsSymptom cluster membershipInflammatory bowel diseaseSymptom burdenBowel diseaseLower symptom burdenPsychological symptoms groupSymptom management optionsHigh symptom burdenRetrospective longitudinal studyLatent transition analysisActive diseaseClinical factorsPain interferenceColitis FoundationSleep disturbancesCluster membershipHigh burdenMultiple symptomsSymptom groupsPhysical symptomsPsychological symptomsLow burdenSymptom clustersLongitudinal changesSymptoms
2017
Symptom clusters in adults with inflammatory bowel disease
Conley S, Proctor DD, Jeon S, Sandler RS, Redeker NS. Symptom clusters in adults with inflammatory bowel disease. Research In Nursing & Health 2017, 40: 424-434. PMID: 28833284, PMCID: PMC5597486, DOI: 10.1002/nur.21813.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSymptom burdenBowel diseaseHigh symptom burden groupSymptom clustersOutcomes Measurement Information System (PROMIS) measuresLower symptom burdenHigh symptom burdenActive disease stateLatent class analysisSymptom management interventionsSymptom cluster groupsSymptom cluster membershipClinical factorsCrohn's diseasePain interferenceBurden groupRetrospective studyColitis FoundationSleep disturbancesFemale genderReduced qualityPhysical symptomsPsychological symptomsSymptoms
2016
Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis
Parian A, Limketkai B, Koh J, Brant SR, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro MD, Rioux JD, Schumm P, Taylor KD, Silverberg MS, Steinhart AH, Hernaez R, Lazarev M. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut 2016, 66: 1390. PMID: 27196594, PMCID: PMC5065377, DOI: 10.1136/gutjnl-2016-311550.Peer-Reviewed Original ResearchConceptsUC diagnosisDisease courseImpact of appendectomyRisk of colectomyTiming of appendectomyIndependent risk factorMilder disease courseSeverity of diseaseDevelopment of UCColectomy rateFuture colectomyEarly appendectomyClinical courseMultivariable analysisRisk factorsAppendectomyColectomyLarge cohortHigh riskPatientsDiagnosisConsortium databaseNational InstituteRiskUC
2005
Enteroscopic Evaluation of the Gastrointestinal Tract in Symptomatic Patients With Hereditary Hemorrhagic Telangiectasia
Proctor DD, Henderson KJ, Dziura JD, Longacre AV, White RI. Enteroscopic Evaluation of the Gastrointestinal Tract in Symptomatic Patients With Hereditary Hemorrhagic Telangiectasia. Journal Of Clinical Gastroenterology 2005, 39: 115-119. PMID: 15681905, DOI: 10.1097/01.mcg.0000150193.15978.f9.Peer-Reviewed Original ResearchConceptsHereditary hemorrhagic telangiectasiaStomach/duodenumHemorrhagic telangiectasiaGastrointestinal bleedingNumber of telangiectasesSymptomatic adult patientsCross-sectional studyAutosomal dominant diseaseDistal stomachSymptomatic patientsAdult patientsMedian numberIndividual patientsGastrointestinal tractPatientsTelangiectasesDuodenumJejunal onesJejunumLarger telangiectasesStomachDominant diseaseBleedingAnemiaTelangiectasia
2003
Diagnosis and Management of Gastrointestinal Bleeding in Patients With Hereditary Hemorrhagic Telangiectasia
Longacre AV, Gross CP, Proctor D, Henderson KJ, Gallitelli M, White R. Diagnosis and Management of Gastrointestinal Bleeding in Patients With Hereditary Hemorrhagic Telangiectasia. The American Journal Of Gastroenterology 2003, 98: 59. PMID: 12526937, DOI: 10.1111/j.1572-0241.2003.07185.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedRetrospective StudiesTelangiectasia, Hereditary HemorrhagicConceptsBlood transfusion requirementsHereditary hemorrhagic telangiectasiaTransfusion requirementsGI bleedingMean HbDrug therapyHHT patientsHemorrhagic telangiectasiaEthinyl estradiol/norethindroneHigher blood transfusion requirementsIndividual patient basisLower mean HbGastrointestinal bleedingMean followRed blood cellsConsecutive patientsEndoscopic treatmentSignificant bleedingMean ageClinical evaluationBleedingPatient basisPatientsOptimal managementAminocaproic acid